Sign in
Not yet taking people in HungaryPhase 2

Tests individualized everolimus dosing in metastatic breast cancer

Tests everolimus, tailored to each person, in adults with metastatic breast cancer.

Key facts

Who runs it
Orszagos Onkologiai Intezet
Where
Budapest XII, HungarySee the site
Registry title
Individualized everolimus therapy in metastatic breast cancer
Status
Not yet recruiting
Phase
Phase 2
People taking part
64 people, planned
Started
1 Jan 2025
Expected to end
31 Dec 2027
Type of study
Interventional
Record updated
19 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with estrogen receptor positive, HER2 negative breast cancer that cannot be removed by surgery or has spread, who have already had hormone-based treatment with a CDK4/6 inhibitor.

Age
Over 18 years
Sex
All sexes can join. Premenopausal women and men must also use a GNRH analogue.
Disease stage
Invasive breast cancer, proven by tissue testing, that is estrogen receptor positive and HER2 receptor negative. It cannot be removed by surgery or has spread. ECOG performance status 0-1.
Earlier treatment
At least one earlier line of hormone-based palliative therapy that included a CDK4/6 inhibitor. Earlier palliative chemotherapy is allowed.
Biomarker or test result
Estrogen receptor positive and HER2 receptor negative tumour.

Main reasons for not taking part

  • Significant heart disease, such as a serious rhythm problem, heart attack or unstable angina within 6 months, long QT syndrome or heart failure
  • Another serious acute or chronic illness that the treating doctor judges would make treatment too risky
  • Pregnancy, or not agreeing to use a non-hormonal method of contraception
  • Known allergy to everolimus, exemestane or their components

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • patient over 18 years of age
  • histologically proven estrogen receptor positive and HER2 receptor negative invasive breast tumour
  • Irresectable or metastatic disease
  • satisfactory overall performance status: ECOG 0-1
  • adequate organ function a. Neutrophil count ≥ 1.5 G/l, platelet count ≥ 100 G/l, haemoglobin ≥ 10 g/dl b. GOT/GPT less than 2.5 times the upper limit of the normal range (5 times in case of liver metastasis) c. bilirubin less than 1,5 times the upper limit of the normal range (except Gilbert's disease where less than 3 times) d. creatinine less than 1,5 times the upper limit of the normal range or eGFR higher than 60 ml/min
  • at least one previous line of endocrine-based palliative therapy that included a CDK4/6 inhibitor
  • previous palliative chemotherapy is allowed
  • Postmenopausal female patient, or if premenopausal female or male patient, simultaneous use of GNRH analogue

Who cannot take part

  • known allergy or hypersensitivity to everolimus, exemestane or their components
  • Known significant cardiac disease: major arrhythmia or significant conduction disturbance (grade 2 or more in severity), infarction or unstable angina within 6 months, collapse of cardiac origin without appropriate therapy, long QT syndrome, heart failure
  • any other serious acute or chronic condition (organic or psychiatric disease, laboratory abnormality, severe pulmonary disease) which, in the opinion of the treating physician, would result in an unacceptable increase in the risk of therapy
  • Pregnancy or if the patient does not agree to use an appropriate non-hormonal method of contraception

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • What did the tests on your tumour show about hormone receptors and the HER2 protein?
  • Have you already had any medicine for your cancer after it spread or became advanced?
  • Have you been treated with a CDK4/6 inhibitor (for example palbociclib, ribociclib or abemaciclib)?

Where in Hungary

  • Orszagos Onkologiai IntezetBudapest XII, HungaryNot yet recruiting

About the trial

What the trial wants to find out

Change in the quality of life in the two study arms, examined with the FACT-B quality of life test

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Individualized everolimus therapy in metastatic breast cancer
Plain-language title
Tests individualized everolimus dosing in metastatic breast cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2023-505590-33-06, who can take part
Record updated
19 March 2025